araag2/HINT huggingface dataset:
Clinical trial NCT02824003 (phase 2, status: completed)
Conditions: type 2 diabetes
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: isis-gcgrrx, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male or female, age 18 to 75

          -  BMI ≥ 25.0 kg/m2 < 36.0 kg/m2

          -  HbA1c ≥ 7.5% and ≤ 10.5%

          -  Type 2 Diabetes Mellitus and on stable dose of Metformin. Patients must have been on a
             stable dose of oral metformin (at least 1000 mg/day) for a minimum of 3 months prior
             to screening evaluation and will be required to continue their stable dose of
             metformin throughout the study. Patients on a stable dose of metformin plus a
             sulfonylurea (SU) or metformin plus a dipeptidyl peptidase-IV (DPPIV) inhibitor for a
             minimum of 3 months prior to Screening evaluation may be allowed

          -  Agree to conduct home-based (fasted) blood glucose testing as directed

        Exclusion Criteria:

          -  Clinically significant abnormalities in medical history or physical exam

          -  Show evidence of uncorrected hypothyroidism or hyperthyroidism

          -  History of liver transplantation or renal dialysis

          -  History of liver disease

          -  History of greater than 3 episodes of severe hypoglycemia within 6 months of screening

          -  Treatment with any other antidiabetic drug(s) other than metformin, SU or DPPIV within
             3 months of screening

          -  History of diabetic ketoacidosis

          -  Any other significant illness or condition that may interfere with the patient
             participating or completing the study

          -  Inability or unwillingness to comply with protocol or study procedures -
Clinical trial NCT02824913 (phase 2, status: terminated)
Conditions: dry eye disease
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: p-321 ophthalmic solution, p-321 ophthalmic solution placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          1. Provide written informed consent

          2. Male or female subjects aged 18 to 80 years

          3. Have a history of predominantly tear-deficient dry eye of mild to moderate severity,
             supported by a previous clinical diagnosis

          4. Have normal lid anatomy

          5. Subjects must:

               1. Remain on current medications for the duration of the study and have been on the
                  current medication regimen at least during the past 28 days

        Exclusion Criteria:

          1. Have undergone refractive eye surgery in either eye during the past 12 months

          2. Have undergone uncomplicated cataract surgery in either eye during the past 3 months

          3. Have undergone previous eyelid surgery in either eye (External blepharoplasty, not
             resulting in exposure or abnormal blinking is allowed)

          4. Have undergone botulinum toxin (BotoxTh1 or equivalent) injection in the periocular
             area within 3 months prior to Visit 1

          5. Subjects that have a systemic, multi-organ disease requiring active medical or
             surgical treatment are excluded with the exception of subjects with SS or GVHD

          6. Have punctal plugs, punctal occlusion, history of nasolacrimal duct obstruction or
             wear scleral lens.

          7. Past or present exposure keratopathy, neurotrophic keratopathy, lagophthalmos, or
             trichiasis
Clinical trial NCT02833350 (phase 2, status: completed)
Conditions: rheumatoid arthritis
ICD codes: M06.9, M05.9, M06.08, M06.00, M06.011, M06.012, M06.019
Drugs: gdc-0853, adalimumab, folic acid, mtx, placebo
SMILES: O, NC1=NC(=O)C2=NC(CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)=CN=C2N1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have a diagnosis of adult-onset RA as defined by the 2010 American College of
             Rheumatology/European League Against Rheumatism Classification Criteria for RA

          -  RA disease activity by joint counts and laboratory markers of inflammation: greater
             than or equal to (>=) 6 tender/painful joints on motion (68 joint count) and >= 6
             swollen joints (66 joint count) at both screening and Day 1 (randomization)

          -  For MTX-inadequate response (IR) participants: must have had an inadequate response to
             MTX

          -  For TNF-IR participants: must have had an inadequate response or intolerance to
             previous treatment with at least 1 and no more than 2 biologic TNF-alpha inhibitors
             and may have also been exposed to no more than one biologic non-TNF-alpha inhibitor

          -  High sensitivity C-reactive protein of >= 0.400 milligrams per deciliter (mg/dL) for
             Cohort 1 and >= 0.650 mg/dL for Cohort 2 at screening

        Exclusion Criteria:

          -  History of or current inflammatory joint disease other than RA or other systemic
             autoimmune disorder

          -  For MTX-IR participants: History of treatment with any TNF inhibitor, including
             biosimilar equivalents and history of treatment with biologic non-TNF-alpha inhibitor
             for RA

          -  For all participants: Previous treatment with cell-depleting therapy including B
             cell-depleting therapy (e.g., anti-cluster of differentiation 20-directed therapy such
             as rituximab), tofacitinib, or other Janus kinase inhibitor(s), or alkylating agents

          -  Current treatment with medications that are well known to prolong the QT interval at
             doses that have a clinically meaningful effect on QT

          -  History of non-gallstone-related pancreatitis or chronic pancreatitis

          -  Evidence of serious uncontrolled concomitant cardiac, neurologic, pulmonary, renal,
             hepatic, endocrine, metabolic, or gastrointestinal disease

          -  Evidence of chronic and/or active hepatitis B or C

          -  Women who are pregnant, nursing (breast feeding), or intending to become pregnant
             during the study or within 60 days after completion of the study
Clinical trial NCT02839200 (phase 2, status: completed)
Conditions: insomnia disorder
ICD codes: F51.05
Drugs: act-541468 5 mg, act-541468 10 mg, act-541468 25 mg, zolpidem, placebo 1, placebo 2
SMILES: CN(C)C(=O)CC1=C(N=C2C=CC(C)=CN12)C1=CC=C(C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Principal inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Male or female aged 18-64 years (inclusive).

          -  Women of childbearing potential must have negative pregnancy tests and use reliable
             methods of contraception up to 30 days after EOT.

          -  Body mass index (BMI): 18.5 ≤ BMI (kg/m2) < 32.0.

          -  Insomnia disorder according to DSM-5 criteria.

          -  Insufficient sleep quantity as collected subjectively in the sleep diary and validated
             objectively by polysomnography.

          -  Insomnia Severity Index score ≥ 15.

        Principal exclusion Criteria:

          -  Any current history of sleep disorder other than insomnia, or any lifetime history of
             related breathing disorder, periodic limb movement disorder, restless legs syndrome,
             circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.

          -  Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week.

          -  Caffeine consumption ≥ 600 mg per day.

          -  Shift work within 2 weeks prior to the screening visit, or planned shift work during
             study.

          -  Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel >
             or= 3 time zones during study.

          -  Hematology or biochemistry test results deviating from the normal range to a
             clinically relevant extent as per judgment of the Investigator.

          -  AST and/or ALT > 2 × ULN and/or direct bilirubin > 1.5 × ULN (except known history of
             Gilbert's syndrome).

          -  Severe renal impairment (known or defined as estimated creatinine clearance < 30
             mL/min).

          -  History or clinical evidence of any disease or medical condition or treatment, which
             may put the subject at risk of participation in the study or may interfere with the
             study assessments.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             the subject's full participation in the study or compliance with the protocol.
Clinical trial NCT02841709 (phase 2, status: completed)
Conditions: insomnia disorder
ICD codes: F51.05
Drugs: act-541468, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Signed informed consent prior to any study-mandated procedure.

          -  Male or female aged ≥ 65 years.

          -  Body mass index (BMI): 18.5 ≤ BMI (kg/m2 ) < 32.0

          -  Insomnia disorder according to DSM-5 criteria.

          -  Self-reported history of insufficient sleep quantity.

          -  Insufficient sleep quantity as collected subjectively in the sleep diary and validated
             objectively by polysomnography.

          -  Insomnia Severity Index score ≥ 15.

        Exclusion Criteria:

          -  Any current history of sleep disorder other than insomnia, or any lifetime history of
             related breathing disorder, periodic limb movement disorder, restless legs syndrome,
             circadian rhythm disorder, rapid eye movement (REM) behavior disorder, or narcolepsy.

          -  Self-reported usual daytime napping ≥ 1 hour per day, and ≥ 3 days per week.

          -  Caffeine consumption ≥ 600 mg per day.

          -  Shift work within 2 weeks prior to the screening visit, or planned shift work during
             study.

          -  Travel ≥ 3 time zones within 1 week prior to the screening visit, or planned travel ≥
             3 time zones during study.

          -  Hematology or biochemistry test results deviating from the normal range to a
             clinically relevant extent as per judgment of the Investigator.

          -  AST and/or ALT > 2 × ULN and/or bilirubin > 1.5 × ULN (except known history of
             Gilbert's syndrome);

          -  Severe renal impairment (known or defined as estimated creatinine clearance < 30
             mL/min);

          -  History or clinical evidence of any disease or medical condition or treatment, which
             may put the subject at risk of participation in the study or may interfere with the
             study assessments.

          -  Any circumstances or conditions, which, in the opinion of the investigator, may affect
             the subject's full participation in the study or compliance with the protocol.
Clinical trial NCT02843659 (phase 2, status: terminated)
Conditions: sjögren's syndrome
ICD codes: D68.61, D69.41, D81.4, E24.1, E26.01, E26.81, E34.0
Drugs: bms-931699, bms-986142, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    inability to meet protocol objectives
  
Eligibility criteria:

        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please
        visit www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Subjects diagnosed or classified as having moderate to severe primary Sjögren's
             Syndrome based on the 2016 ACR-EULAR Sjögren's Syndrome Classification Criteria for at
             least 16 weeks prior to screening

          -  ESSDAI ≥ 5 including disease activity (any score > 0) in at least one of the following
             domains: Glandular, Articular, Hematological, Biological, Lymphadenopathy

          -  Positive anti-SS-A/Ro and/or anti-SS-B/La autoantibody

          -  Unstimulated whole saliva secretion > 0.01 ml/min

          -  Women of childbearing potential (WOCBP) must have a negative serum or urine pregnancy
             test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours prior to
             the start of study drug and must not be pregnant or breastfeeding. Male and female
             subjects must be willing to adhere to protocol-mandated highly effective contraception
             for the duration of the study and for the protocol-specified follow up period.
             Hormone-based contraceptive methods are not permitted

        Exclusion Criteria:

          -  Secondary Sjögren's syndrome or the presence of any other systemic autoimmune disease
             (eg, RA, SLE, multiple sclerosis, vasculitis)

          -  Very severe primary Sjögren's syndrome or severe complications of primary Sjögren's
             syndrome at the time of the screening visit

          -  Active systemic or latent bacterial (including tuberculosis), viral or fungal
             infection, evidence of current or chronic Hepatitis B or C infection, or HIV infection

          -  Any significant concurrent medical condition at the time of screening or baseline
             visit

          -  Use of methotrexate, cyclophosphamide, cyclosporine, tacrolimus, azathioprine,
             mycophenolate mofetil (MMF) or leflunomide within 12 weeks of screening visit

          -  Previous treatment with biologics therapies either marketed or in development within 6
             months prior to screening visit

          -  Treatment started or an unstable dose of hydroxychloroquine within 8 weeks of
             screening visit

          -  Oral corticosteroids > 10 mg/day within 14 days of dosing (Day 1), corticosteroid
             therapy ≥ 1 mg/kg during the 4 weeks preceding enrollment, or intravenous,
             intramuscular or intra-articular corticosteroids within 4 weeks of screening visit

        Other protocol defined inclusion/exclusion criteria could apply
Clinical trial NCT02846324 (phase 2, status: completed)
Conditions: idiopathic pulmonary fibrosis, hypoxemia
ICD codes: J84.112
Drugs: gbt440, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Documented diagnosis of IPF.

          -  Oxygen desaturation with exercise.

          -  Completion of the baseline 6MWT

          -  Weight ≥ 50 kg

          -  Male or female of child bearing potential willing and able to use highly effective
             methods of contraception from study start to 3 months after the last dose of study
             drug.

        Exclusion Criteria:

          -  FEV1/FVC < 70%.

          -  Subjects on supplemental oxygen therapy at rest.

          -  History of other interstitial lung diseases.

          -  Significant polycythemia.

          -  Female who is breast-feeding or pregnant.

          -  Known current malignancy or history of malignancy within the last 2 years prior to
             screening.

          -  Use of cytotoxic and/or immunosuppressant medications within 30 days screening.

          -  Hospitalization due to an exacerbation of IPF within 30 days of screening

          -  Subject plans to begin or has commenced pulmonary rehabilitation within 30 days of
             screening

          -  Corticosteroids (> 10 mg per day of prednisone or an equivalent) within 30 days of
             screening.

          -  Current smoker or history of smoking within 3 months of screening.

          -  Currently or, in the opinion of the investigator, soon to be listed for lung
             transplant.

          -  History of unstable or deteriorating cardiac or pulmonary disease (other than IPF)
             within 6 months of screening.

          -  Any condition possibly affecting drug absorption.

          -  Participated in another clinical trial of an investigational drug (or medical device)
             within 30 days or 5-half-lives, whichever is longer, prior to screening, or is
             currently participating in another trial of an investigational drug (or medical
             device).

          -  Subject who, for any reason, is deemed by the investigator to be inappropriate for
             this study.
Clinical trial NCT02847650 (phase 2, status: terminated)
Conditions: parkinson disease
ICD codes: G20
Drugs: placebo, pf-06649751
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study b7601011 was terminated on 29 jan 2018 due to lack of efficacy in moderate/advanced
    parkinson's disease.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Females of non-childbearing potential and/or male subjects

          -  Clinical diagnosis of Parkinson's disease.

          -  Parkinson's Disease Hoehn & Yahr Stage I-III inclusive

          -  Treatment naïve or history of prior incidental treatment with dopaminergic agents for
             no more than 28 days

          -  Able to refrain from any Parkinson's disease medication not permitted by the protocol.

        Exclusion Criteria:

          -  History or presence of atypical Parkinsonian syndrome.

          -  Severe acute or chronic medical or psychiatric condition or cognitive impairment or
             laboratory abnormality.

          -  Any condition possibly affecting drug absorption.

          -  Participation in other studies involving investigational drug(s), or treatment with
             any investigational drug within 30 days.
Clinical trial NCT02850874 (phase 2, status: withdrawn)
Conditions: pancreatic neoplasms, pancreatic adenocarcinoma
ICD codes: C25.3, C22.0, C22.1, C4A.9, C7B.1, D09.9, C4A.0, C4A.31
Drugs: gemcitabine
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    no accrual rate
  
Eligibility criteria:

        Inclusion Criteria:

          -  Primary diagnosis of pancreatic ductal adenocarcinoma (PDAC) confined to the head of
             the pancreas classified as T1-T3 with one or more of the following high-risk clinical
             features:

               -  Carbohydrate antigen (CA) 19-9 greater than 1,000 U/mL with a normal bilirubin;

               -  Vascular involvement; and/or

               -  Suspicious regional lymphadenopathy

          -  Intention to undergo open pancreaticoduodenectomy (standard Whipple or
             pylorus-preserving pancreaticoduodenectomy) as treatment for PDAC

          -  Adequate clinical condition to undergo preoperative (neoadjuvant) hyperthermic
             intraperitoneal chemotherapy

          -  Adequate clinical condition to undergo perioperative systemic chemotherapy

          -  White blood cell count of at least 3000/mL

          -  Platelet count of at least 100,000/mL

          -  Normal creatinine (< 2 mg/dL) or creatinine clearance of at least 50 mL/min

          -  Willing and able to give informed consent

        Exclusion Criteria:

          -  Evidence of locoregional spread (carcinomatosis of peritoneal surfaces, mesenteric
             arteries, or body/tail of pancreas) or distant (liver, lung, or other) metastases
             (histological, CT, or MRI confirmation)

          -  Non-curative intent of treatment (≥R2 resection)

          -  Body mass index (BMI) > 35

          -  Previous history of pancreatic resections for tumors in the body and/or tail of the
             pancreas, distal cholangiocarcinoma, duodenal carcinoma, neuroendocrine tumors,
             cyst-adenocarcinoma, or solid and papillary tumors.

          -  Unstable or uncompensated respiratory or cardiac disease

          -  Severe hepatic or renal dysfunction

          -  Bleeding diathesis or coagulopathy

          -  Pregnant or nursing women
Clinical trial NCT02854631 (phase 2, status: completed)
Conditions: alcoholic hepatitis (ah)
ICD codes: G62.1, G72.1, I42.6, K70.0, K29.20, K29.21, K70.10
Drugs: selonsertib, prednisolone, placebo
SMILES: [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Willing and able to give informed consent prior to any study specific procedures being
             performed. In individuals with hepatic encephalopathy (HE) which may impair
             decision-making, consent will be obtained per hospital procedures (eg, by Legally
             Authorized Representative)

          -  Clinical diagnosis of severe AH

               -  Maddrey's Discriminant Function (DF) ≥ 32 at screening

        Key Exclusion Criteria:

          -  Pregnant or lactating females;

          -  Other causes of liver disease including chronic hepatitis B (hepatitis B surface
             antigen [HBsAg] positive), chronic hepatitis C (HCV RNA positive), acetaminophen
             hepatotoxicity, biliary obstruction, and autoimmune liver disease;

          -  Serum aspartate aminotransferase (AST) >400 U/L or alanine aminotransferase (ALT) >300
             U/L;

          -  Model for End Stage Liver Disease (MELD) >30 at screening;

          -  Maddrey's DF >60 at screening;

          -  Grade 4 Hepatic Encephalopathy (HE) by West Haven criteria;

          -  Concomitant or previous history of hepatocellular carcinoma;

          -  History of liver transplantation;

          -  HIV Ab positive;

          -  Clinical suspicion of pneumonia;

          -  Uncontrolled sepsis;

          -  Uncontrolled gastrointestinal (GI) bleeding or controlled GI bleeding within 7 days of
             screening that was associated with shock or required transfusion of more than 3 units
             of blood;

          -  Type 1 hepatorenal syndrome (HRS) or renal failure defined as a serum creatinine >221
             μmol/L (>2.5 mg/dL) or the requirement for renal replacement therapy;

          -  Individuals dependent on inotropic (eg, epinephrine or norepinephrine) or ventilatory
             support (ie, endotracheal intubation or positive-pressure ventilation);

          -  Portal vein thrombosis;

          -  Acute pancreatitis;

          -  Cessation of alcohol consumption for more than 2 months before Baseline/ Day 1

        Note: Other protocol defined Inclusion/ Exclusion criteria may apply.